

# IRBMED SEMINAR SERIES

Multi-Site Research - The Accepting and Ceding of IRB Oversight:  
What Investigators and Study Teams Need to Know



Ford Auditorium  
April 10, 2016  
9:00am – 11:30pm

## AGENDA

<b>Welcome &amp; Introduction</b>	Judith Birk, JD	<b>9:00 am</b>
<b>Institutional Decisions for Ceding and Accepting IRB Oversight</b>	Lois Brako, Ph.D. and Judy Birk, JD	9:10 am
<b>Ceding IRB Oversight</b>	Angela Faber, BS, CIP	9:40 am
<b>Break and snacks</b>	-----	10:05 am
<b>Research Pharmacy: An Ancillary Review</b>	Amy Skyles, PharmD	10:20 am
<b>Accepting IRB Oversight</b>	Judith Birk, JD and Robin Sedman, MSN, M.Ed.	10: 40 am
<b>Mock IRB</b>		11:00 am
<p>This installment in our series of mock IRB meetings provides insight into IRB review of a serious adverse event at external site when IRBMED is serving as the IRB of Record for the site. This will be followed by a Q&amp;A session with IRBMED Board Members comprising the mock IRB:</p>		
Ann Dillon, BS, CIP – Regulatory Team	Alan Sugar, MD, Chair Amy Filbrun, MD, Vice Chair Amy Skyles, PharmD Corey Zolondek, PhD Duke Morrow, MDiv, DMin Judith Avery, MA	
<b>End</b>	-----	<b>11:30 am</b>